OriCAR-017 not checked

OriCell Therapeutics Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Relapsed and/or Refractory Multiple Myeloma, Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorders, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias and 7 more
Main trialPhase 1/2
“An open label, dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of OriCAR-017 in R/RMM”In the company’s words, NCT06182696 on ClinicalTrials.gov

Other drugs for Relapsed and/or Refractory Multiple Myeloma

All 133 drugs for Relapsed and/or Refractory Multiple Myeloma

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 30 Nov 2026 OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
Phase 1Recruiting 12 Dec 2026 A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow OriCAR-017

Following is part of Solo: you see every change to OriCAR-017 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in